We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi/Regeneron’s LDL-Lowering Praluent Beats Repatha to U.S. Market
Sanofi/Regeneron’s LDL-Lowering Praluent Beats Repatha to U.S. Market
The FDA Friday gave the green light to Sanofi and Regeneron’s cholesterol-lowering drug Praluent, beating Amgen’s Repatha in a race to be the first PCSK9 inhibitor in the U.S.